Innovo announces data from Phase II post-thyroidectomy scar treatment trial

Innovo Therapeutics has reported positive results from its Phase II clinical trial of INV-001, a treatment for reducing post-thyroidectomy scars. Conducted at four hospitals, including Severance Hospital in Seoul, the trial involved 77 patients with wounds larger than 3cm. Participants applied INV-001 twice daily for 12 weeks, with efficacy measured by the Patient and Observer Scar Assessment Scale (POSAS) at week 12.

The study demonstrated significant scar reduction, particularly in the high-dose group, which showed a 24.5% decrease in scar size compared to the placebo. INV-001 was well-tolerated, with no serious adverse events reported. The high-dose group also exhibited statistically significant improvements in the Overall Opinion score on the POSAS Observer scale at 12 weeks, with trends of scar improvement noted at three and six weeks.

Pharmacokinetic analysis showed low blood concentrations of INV-001, and safety assessments indicated all adverse reactions were predictable and site-specific, with no serious incidents.